Drug DevelopmentVistaGen introduced PH284, another neuroactive spray in its pipeline, for the treatment of cancer cachexia, and reported positive P2a results.

Financial StabilityVistaGen has $97.6M in cash, providing financial runway through FY26.

Bears Say

EarningsVistaGen reported F3Q25 results with a net loss of ($14.1M).

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

1.79% Insiders

7.57% Mutual Funds

41.12% Other Institutional Investors

41.76% Public Companies and Individual Investors

Detailed Ownership Overview >

VTGN FAQ

What was VistaGen Therapeutics’s price range in the past 12 months?

VistaGen Therapeutics lowest stock price was $1.90 and its highest was $4.21 in the past 12 months.

What is VistaGen Therapeutics’s market cap?

VistaGen Therapeutics’s market cap is $68.11M.

When is VistaGen Therapeutics’s upcoming earnings report date?

VistaGen Therapeutics’s upcoming earnings report date is Aug 07, 2025 which is in 50 days.

How were VistaGen Therapeutics’s earnings last quarter?

VistaGen Therapeutics released its earnings results on Jun 17, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.497 by $0.067.

Is VistaGen Therapeutics overvalued?

According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does VistaGen Therapeutics pay dividends?

VistaGen Therapeutics does not currently pay dividends.

What is VistaGen Therapeutics’s EPS estimate?

VistaGen Therapeutics’s EPS estimate is -0.47.

How many shares outstanding does VistaGen Therapeutics have?

VistaGen Therapeutics has 28,862,085 shares outstanding.

What happened to VistaGen Therapeutics’s price movement after its last earnings report?

VistaGen Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.497. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of VistaGen Therapeutics?

Currently, no hedge funds are holding shares in VTGN

VistaGen Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-46.28%

Trailing 12-Months

Asset Growth

-29.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

VistaGen Therapeutics

VistaGen Therapeutics, Inc. (VTGN) is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines for central nervous system (CNS) disorders. The company primarily works on creating therapies that address major depressive disorder, social anxiety disorder, and other CNS-related conditions. VistaGen's approach involves using its proprietary technologies to advance its pipeline of novel drug candidates aimed at improving the quality of life for individuals suffering from these disorders.

VTGN Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a positive sentiment due to the significant progress in clinical trials, a robust and diverse product pipeline, and a strong financial position. However, increased R&D expenses and net loss were notable concerns.Read More>